Actively Recruiting
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Updated on 2025-10-08
216
Participants Needed
2
Research Sites
124 weeks
Total Duration
On this page
Sponsors
A
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead Sponsor
E
Erasmus Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.
CONDITIONS
Official Title
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The subject is an adult
- Has a diagnosis of AE
- Receives dupilumab 300 mg every 2 weeks for the treatment of AE
- Has controlled disease according to the Treat-to-Target criteria
- Agrees to the possibility that the dosage of dupilumab will be lowered
- Has voluntarily signed and dated an informed consent prior to any study related procedure
You will not qualify if you...
- The subject uses or initiates another systemic immunomodulating therapy for AE or another diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Amsterdam University Medical Centers
Amsterdam, North Holland, Netherlands, 1105 AZ
Actively Recruiting
2
Erasmus Medical Center
Rotterdam, South Holland, Netherlands, 3015 GD
Not Yet Recruiting
Research Team
P
Phyllis I Spuls, MD PhD
CONTACT
A
Anouk GM Caron, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here